LINACLOTIDE

Summary

Linaclotide is a small peptide agonist of intestinal guanylate cyclase-C receptors used orally to treat chronic constipation and irritable bowel syndrome ^[2]. It is minimally absorbed from the gastrointestinal tract, with the drug and its active metabolite not measurable in milk and considered acceptable during breastfeeding ^[1], and it has not been linked to serum enzyme elevations or clinically apparent liver injury during treatment ^[2]. Comparative reviews position it alongside other agents with differing mechanisms for chronic constipation, supporting an individualized treatment approach and including effects on patient symptoms and quality of life ^[4]. Backed by approved prescription status, multiple meta-analyses, and trials enrolling tens of thousands, the human evidence for linaclotide as an administered therapeutic is strong; the supplied abstracts emphasize safety and tolerability rather than head-to-head efficacy magnitudes.

Sources

1. 1. Linaclotide. Drugs and Lactation Database (LactMed) Drugs and Lactation Database (LactMed), 2024.
2. 2. Linaclotide. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, 2019.
3. 4. Efficacy, safety, patient symptoms, and QoL of three drugs for chronic constipation treatment BMC Gastroenterology, 2023.

For educational purposes only.